
One of Jensen Huang's Ambitious Goals Might Make Nvidia Its Own Worst Enemy
The advent and proliferation of the internet in the mid-1990s was a can't-miss trend that captivated the attention of everyday investors. Since this moment, numerous other game-changing innovations have come along that have promised pie-in-the-sky addressable markets. This includes business-to-business e-commerce, genomics, 3D printing, and the metaverse, to name a few hot trends.
But over the last three decades, no trend has come particularly close to rivaling what the internet did for corporate America... until now.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
The evolution of artificial intelligence (AI) looks to be the next leap forward for the tech industry and society as a whole. The vastness of this game-changing opportunity, which allows AI-empowered software and systems to make split-second decisions without human intervention, is reflected in PwC's estimate that AI will add $15.7 trillion to the global economy in 2030.
A $15.7 trillion addressable market means a lot of companies are going to be winners, from hardware to actual application. However, no company has been a bigger beneficiary of the AI revolution than Nvidia (NASDAQ: NVDA).
The potential problem is that one of Nvidia's biggest perceived competitive advantages might also be its undoing.
Innovation comes first for Nvidia and CEO Jensen Huang
Since 2022 came to a close, shares of Nvidia have advanced by more than 870%, with the company tacking on over $3 trillion in market cap and completing a historic 10-for-1 forward split. Though Nvidia's aggregate percentage return has lagged Palantir Technologies, Nvidia's valuation soared quicker than any megacap stock in history.
Nvidia's outperformance is directly reflective of its ideal positioning in AI-accelerated data centers. The company's Hopper (H100) graphics processing units (GPUs) and successor Blackwell GPU have been the preferred options in high-compute data centers. In other words, there's a very high probability that Nvidia's hardware is behind the latest generative AI solutions and the training of most large language models.
Being at the leading edge of the hottest trend on Wall Street over the last three decades has its perks. With demand for AI-GPUs handily swamping supply, Wall Street's AI darling has been able to charge a veritable arm and a leg for its hardware. Last year, Nvidia's Hopper chip was flying off the shelves with a price tag north of $40,000. For the sake of comparison, Advanced Micro Devices was selling its Instinct MI300X series chips for between $10,000 and $15,000.
The ability to charge a premium for its hardware sent Nvidia's gross margin soaring. After consistently producing a generally accepted accounting principles (GAAP) gross margin in the low-to-mid 60% range prior to the rise of AI, Nvidia saw its GAAP gross margin explode to as high as 78.4% in the fiscal first quarter one year ago (the company's fiscal year ends in late January).
But it can be argued that Nvidia's greatest competitive advantage is its innovation, which is led by CEO Jensen Huang.
Huang's aggressive ambition is to bring a next-generation AI chip to market on an annual basis. It began with the Hopper and Blackwell, and is expected to continue with the release of Blackwell Ultra in the latter-half of this year, Vera Rubin in the second-half of 2026, and Vera Rubin Ultra in the latter-half of 2027.
As you might have surmised, Vera Rubin and Vera Rubin Ultra will be running on a new processor, known as "Vera." This processor should be capable of doubling the processing performance of Blackwell Ultra, with considerably improved memory capacity and memory bandwidth than predecessor chips.
The key point being that Huang wants to keep Nvidia in its decisive leadership position on the compute front, which in turn should help the company charge a premium price for its hardware, relative to external competitors like AMD and China-based Huawei.
Could Jensen Huang's accelerated innovation timeline be Nvidia's worst enemy?
For virtually all publicly traded companies, innovation is paramount to success. Huang's aggressive spending on research to develop faster and more-efficient AI-GPUs is something that Wall Street and investors would almost universally cheer.
But there's a very real possibility that Jensen Huang's accelerated innovation timeline may do more harm than good for his company. While it does appear that Nvidia will hang onto its compute advantages for the foreseeable future, there are far more considerations businesses have to take into account than just compute ability.
Imagine for a moment that you're a " Magnificent Seven" business and one of Nvidia's top customers that just dropped tens of billions of dollars on the company's hardware to cement your spot as an AI leader. Now imagine your AI-GPUs massively depreciating in value one or two years later because of Nvidia's accelerated innovation cycle. Are you really expected to drop $10 billion-plus every year or two for the latest chip? Highly unlikely.
What's interesting is that many of Nvidia's leading customers by net sales within the Mag-7 are internally developing AI-GPUs and solutions of their own. Though this hardware isn't going to externally compete against Hopper, Blackwell, or the company's successor chips, it'll be notably cheaper than Nvidia's GPUs. Further, since these internally developed chips aren't backlogged like Nvidia's chips, they'll be far more accessible. This points to Nvidia's largest customers by net sales delaying their upgrade cycles.
Nvidia's GAAP gross margin has come under pressure over the last year. NVDA Gross Profit Margin (Quarterly) data by YCharts.
We might also see Nvidia's largest revenue customers opt for older chips as they depreciate. Though Huang's entire premise of introducing a new GPU annually is to sustain his company's pricing power, his own accelerated development timeline could crater Nvidia's GAAP gross margin as businesses purchasing their own hardware -- not those leasing data center space -- trade down to less-costly but still quick alternatives.
Jensen Huang's aggressive innovation cycle is also potentially damaging to data-center leasing models, such as the newly public CoreWeave (NASDAQ: CRWV). Between 2022 and 2024, CoreWeave used extensive debt financing to acquire approximately 250,000 GPUs, many of which are Nvidia's Hopper chip. The value of these chips will likely depreciate rapidly with Wall Street's AI darling introducing an advanced GPU annually. Businesses wanting cutting-edge compute capabilities might pass on CoreWeave's data centers faster than investors might realize.
While there's no question that Nvidia's AI-GPUs are superior to the competition in compute ability, there's far more that goes into a business's purchasing decision. There's a very real possibility that Huang's own ambitious GPU innovation timeline acts as his company's own worst enemy in the years to come.
Should you invest $1,000 in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!*
Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 2, 2025

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
16 minutes ago
- Globe and Mail
Strategy (MSTR) Buys Another $110 Million of Bitcoin
Strategy (MSTR) continues to purchase Bitcoin (BTC) even as the price rises. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In the past week, the software company turned serial Bitcoin acquirer bought an additional 1,045 BTC for $110.2 million. The company, led by founder Michael Saylor, paid an average purchase price of $105,426 each for its latest Bitcoin accumulation. Strategy, formerly known as MicroStrategy, now owns 582,000 Bitcoin worth $62.5 billion. The company is the largest corporate owner of BTC in the world. Strategy's average purchase price for its Bitcoin holdings is $70,086 per digital token. Funding Purchases Last week's buys were funded via at-the-market sales of Strategy's preferred stock, according to a regulatory filing with the U.S. Securities and Exchange Commission (SEC). The company remains committed to its focus on aggressively acquiring Bitcoin. Strategy's stock has risen 25% this year to trade at $374.47 per share. The price of Bitcoin is currently right around $107,500, having gained 12% on the year. Is BTC a Buy? Most Wall Street firms don't offer ratings or price targets on Bitcoin, so we'll look instead at its three-month performance. As one can see in the chart below, the price of BTC has risen 34.14% in the last 12 weeks.


Globe and Mail
16 minutes ago
- Globe and Mail
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw first-quarter 2025 sales decline nearly 50% year over year to $1.12 billion. Humira had already lost exclusivity in ex-U.S. markets in 2018. Despite the steep decline, ABBV's ex-Humira platform grew more than 21% year over year (on a reported basis) in the first quarter of 2025, driven by its newer immunology drugs, Skyrizi and Rinvoq. The company successfully launched Skyrizi and Rinvoq across Humira's major indications and a distinct new indication, atopic dermatitis. Both drugs showed strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions: ulcerative colitis (UC) and Crohn's disease (CD). Strong immunology-market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs' future growth. On the back of this continued momentum, AbbVie raised its previously issued guidance by around $900 million and now expects to record $24.7 billion from the combined sales of both drugs this year. Our model estimates the combined sales figure to be around $24.85 billion. ABBV's Competition in the Immunology Space The targeted market is highly competitive. A key player in this area is Johnson & Johnson JNJ, which already markets blockbuster medications, Stelara and Tremfya. Both of these J&J drugs are approved across multiple immunology indications, including UC and CD indications. Since Stelara lost U.S. LoE earlier this year, J&J has shifted focus to Tremfya to maintain its foothold in the immunology space. Another pharma giant expanding its presence in immunology is Eli Lilly LLY, following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly's first immunology drug approved for a type of IBD in the United States and plays a key role in building out its immunology portfolio. This Lilly drug received FDA approval for the CD indication in January. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.48 times forward earnings, a tad lower than its industry's average of 15.12. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.38. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has declined from $12.30 per share to $12.28, while that for 2026 has increased from $13.97 to $14.05 over the past 60 days. AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report


Globe and Mail
16 minutes ago
- Globe and Mail
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. The drug has played an instrumental role in driving Merck's steady revenue growth in the past few years. Keytruda's sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Keytruda is presently approved to treat nine indications in earlier-stage cancers in the United States. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects continued growth from Keytruda, particularly in early lung cancer. However, Merck is heavily reliant on Keytruda. Though Keytruda may be Merck's biggest strength, it can also be argued that the company is excessively dependent on the drug, and it should look for ways to diversify its product lineup. There are rising concerns about the firm's ability to grow its non-oncology business ahead of the upcoming loss of exclusivity of Keytruda in 2028. Also, competitive pressure might increase for Keytruda in the near future. In 2024, Summit Therapeutics SMMT reported positive data from a phase III study (conducted in China by partner Akeso) in patients with locally advanced or metastatic NSCLC, in which its lead pipeline candidate, ivonescimab, a dual PD-1 and VEGF inhibitor, outperformed Keytruda. Summit believes ivonescimab has the potential to replace Keytruda as the next standard of care across multiple non-small cell lung cancer (NSCLC) settings. Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors. In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for patients with certain types of melanoma and NSCLC. Merck and Moderna are conducting pivotal phase III studies on V940, in combination with Keytruda, for earlier-stage and adjuvant NSCLC and adjuvant melanoma. Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. It is under review in the United States and an FDA decision is expected in September. Merck is also pinning hopes on the newly launched pulmonary arterial hypertension (PAH) drug Winrevair to boost its top line once Keytruda loses exclusivity. Keytruda generated sales of $7.21 billion in the first quarter of 2025, rising 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years. MRK's Price Performance, Valuation and Estimates Merck's shares have lost 19.6% so far this year against an increase of 0.3% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.55 forward earnings, lower than 15.12 for the industry and its 5-year mean of 12.89. Image Source: Zacks Investment Research Estimates for both 2025 and 2026 earnings have declined over the past 60 days. Merck has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report